Kornimate/medical-research-clean huggingface dataset:
effects of the postbiotic blend abb c3 on adiposity and glucose metabolism in children and adolescents

Conditions: Obesity, Childhood; Obesity, Adolescent

Summary: this study investigates the effects of a postbiotic combination called abb c3 on reducing body fat and improving metabolic health in children and teenagers. the study consists of a 3-month trial with half participants taking abb c3 and the other half a placebo, monitoring body composition and blood markers. afterward, participants can continue with abb c3 for an additional 3 months. the goal is to determine if abb c3 is a safe and effective way to help young people improve their health by reducing body fat.

the study focuses on evaluating the effects of a combination of postbiotics called abb c3 in reducing body fat and improving glucose metabolism. the study proposes a randomized, double-blind clinical trial with participants (aged 8-18 years) randomized into the abb c3 supplement group or a placebo group. over a period of 3 months, body composition and relevant blood parameters will be monitored (study phase). subsequently, all participants will be offered to continue with the abb c3 supplement for an additional 3 months, constituting the follow-up phase. the study protocol includes collecting data on possible adverse events. blood samples and dxa scans will be performed to assess changes in body composition and metabolic health parameters. in summary, the study aims to determine the efficacy and safety of the abb c3 postbiotic in helping reduce body fat and improve metabolic profiles in children and adolescents.

Eligibility criteria:
inclusion criteria: * age between 8- and 18-year-old * obesity (bmi-sds \> 2) exclusion criteria: * antibiotic or pre/pro/postbiotic consumption 2 - 4 weeks prior to starting the study * chronic diseases affecting glucose or lipid metabolism * chronic medication affecting glucose or lipid metabolism, or inducing a pro-inflammatory state * history of bariatric surgery * diabetes requiring insulin treatment * severe intellectual disability * pregnancy * individuals taking medications that may alter appetite or weight, with a recent change in prescription within the last 3 months or anticipated changes during the 2 months of participation

Keywords: obesity postbiotics
clinical evaluation of reproducibility of keratometric measurements and influencing factors in cataract patients

Conditions: Cataract; Dry Eye

Summary: the investigational device is an approved biometry device to perform biometric measurements preoperatively to calculate the needed iol power. first, two native measurements at the iol master will be performed. thereafter randomly assigned artificial tears are instilled in the eye and biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes. at least 24hours after those measurements, two native measurements at the iol master will be performed. thereafter, the not yet used artificial tears are instilled in the eye and biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes. examinations will be implemented in accordance with the approved investigational plan on subjects and includes: repeated biometry without and with artificial tear drops.


Eligibility criteria:
inclusion criteria: * diagnosed uni- or bilateral age-related cataract * age 40 to 95 * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant exclusion criteria: * corneal abnormality (corneal scaring) * usage of artificial tears/eyedrops 24h before the examination * necessity of any topical therapy of the eye (i.e. glaucoma) * active ocular or nasal allergies or corneal or conjunctival infection * abnormality of the nasolacrimal drainage apparatus * dry eye severity level 4 (severe and/or disabling constant discomfort and visual symptoms, marked conjunctival injection, filamentary keratitis, mucus clumping, tear debris, ulceration, trichiasis, keratinization, symblepharon) * lid deformities * preceding ocular surgery or trauma * pregnancy * lactation * uncontrolled systemic or ocular disease
effects of ono-2506po in patients with alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to establish the presence of an effect of treatment with ono-2506po in patients with alzheimer's disease, based upon cognitive and global scales.


Eligibility criteria:
inclusion criteria: * diagnosis of probable alzheimer's disease using nincds/adrda criteria * standardized mmse score of 13 to 24 points (inclusive) * modified hachinski score equal or less than 4 exclusion criteria: * serious systemic disease that may preclude survival to study completion * other illnesses that may include dementive features
a safety, tolerability and pharmacokinetics study of topical ointment yr001 in adult healthy volunteers

Conditions: Atopic Dermatitis; Psoriasis

Summary: this study is to evaluate the safety, tolerability, and pharmacokinetics of yr001 topical ointment in healthy adult subjects.


Eligibility criteria:
inclusion criteria: 1. written informed consent obtained from the subject 2. male or female subject is aged between 18 and 65 years 3. subject has a weight of at least 50 kg and a body mass index (bmi) between 18.0 and 30.0 kg/m2 4. free from any clinically relevant illness or disease incl. skin disorder that may adversely affect the safety of the subject or the integrity of the study exclusion criteria: 1. presence or history of a clinically significant medical condition or other condition that might interfere with the safety, tolerability and pk assessment of ointment yr001, or place the subject at an unacceptable risk as a subject in this study. 2. pregnant or lactating women. 3. any skin tattoo, scar, cuts, bruises, or other skin damage, including excessive uv exposure, at the possible ip application sites. 4. have concomitant skin disease or infection (e.g., acne, impetigo) or presence of skin comorbidities in the skin areas to be dosed that may interfere with study assessments and treatment response. 5. have active infectious disease. 6. subjects treated with another investigational drug, biological agent, or device 7. participation in another interventional clinical trial before entering, or during the trial, or previous participation in this clinical trial. 8. evidence of clinically important cardiac conduction abnormalities at screening as judged by ecg. 9. active untreated mental or psychiatric disorder. 10. any major surgery within 6 months of screening. 11. malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. 13. drug or alcohol abuse history.
correction of anisometropic amblyopia in children.

Conditions: Amblyopia; Anisometropic Amblyopia; Anisometropia and Aniseikonia; Refractive Errors

Summary: anisometropic amblyopia among children in school age may affects quality of life and educational progress of children.

correction of anisometropic amblyopia depends on type of refractive error and axial length of the eye. in this study, we will asses the types of anisometropia found in children at school age and investigate possible ways for correction of this type of amblyopia.

Eligibility criteria:
inclusion criteria: * anisometropic amblyopia. * children at school age ranged from 4 to 12 years old. exclusion criteria: * emmetropia children. * children had undergone any intraocular surgeries. * other types of amblyopia.

Keywords: amblyopia axial refractive error anisometropia
lensage to reveal biological age

Conditions: Ophthalmology; Lens Opacities; Biological Age

Summary: assessment of aging is central to health management. compared to chronological age, biological age can better reflect the aging process and health status; however, an effective indicator of biological age in clinical practice is lacking. human lens accumulates biological changes during aging and is amenable to a rapid and objective assessment. therefore, the investigators will develop lensage as an innovative indicator to reveal biological age based on deep learning using lens photographs.


Eligibility criteria:
inclusion criteria: * ages from 20 to 100 years * have anterior segment photographs * have ophthalmic and physical examination records exclusion criteria: * have a history of previous eye surgery, eye trauma, or ocular diseases that can cause complicated cataracts * baseline information missing
comparison of physical activity level between patients with bronchiectasis and healthy subjects

Conditions: Bronchiectasis

Summary: the purpose of this study is to compare physical activity levels between patients with bronchiectasis and healthy subjects. we hypothesize that patients with bronchiectasis will have lower levels of physical activity, since physical activity levels is affected by reduced exercise tolerance, severity of disease and other disease related symptoms and conditions.

physical activity limitation in chronic respiratory diseases is caused by many factors including respiratory, hemodynamic, and peripheral muscle weakness. bronchiectasis is characterized by irreversible widening of the medium-sized airways, with inflammation, chronic bacterial infection and destruction of the bronchial walls. in addition to pulmonary function worsening, extra pulmonary features such as reduced peripheral muscle endurance can be a significant physical problem which causing a decrease in physical activity levels. despite physical activity is considered to be essential for the management of chronic respiratory diseases, there is a lack of scientific study, which compares physical activity levels between patients with bronchiectasis and healthy subjects. this study will assess physical activity level, exercise capacity, quality of life and peripheral muscle strength in patients with bronchiectasis compared to healthy subjects.

Eligibility criteria:
inclusion criteria: inclusion criteria of the bronchiectasis group: 1. diagnosis of bronchiectasis 2. being 18 years of age or older 3. able and willing to complete the informed consent process. 4. able to walk and co-operate exclusion criteria: exclusion criteria of bronchiectasis group: 1. unstable medical condition 2. to have severe neurological, orthopedic problems or severe heart failure. the control group will consist of healthy subjects.

Keywords: physical activity levels bronchiectasis
inhaled mannitol and ciliary beat frequency in copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the main purpose of the study is to evaluate the effect of mannitol on the cilia's beat frequency (ciliary beat frequency) in copd patients.


Eligibility criteria:
inclusion criteria: * copd

Keywords: copd
battery-preserving stimulation patterns for deep brain stimulation

Conditions: Parkinsons Disease; Essential Tremor

Summary: the purpose of this research study is to test effectiveness of different deep brain stimulation (dbs) stimulation patterns on symptoms that may also improve the life of the battery. if these patterns are effective, the implanted batteries will be drained more slowly and last longer than currently expected. an increase in battery life may reduce the number of surgeries needed to replace them.

deep brain stimulation (dbs) is an effective surgical therapy for medication-refractory symptoms of parkinson's disease, tremor, and dystonia. patients implanted with dbs experience a significant improvement of their symptoms with relatively low risk of intolerable side effects. implanted patients must undergo repeat surgeries to replace the implantable pulse generators/batteries (ipg) approximately every 2 to 5 years. the dbs program (at the university of florida) has studied battery consumption and has been interested in potential strategies to extend the life of the ipg to reduce the need for frequent battery replacement surgeries, while improving symptom-relief, patient satisfaction, and the potential associated financial burdens. the research study will evaluate the effects of novel stimulation patterns on tremor, bradykinesia, rigidity and gait in parkinson's disease and essential tremor patients.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease or essential tremor by strict criteria * deep brain stimulation (dbs) already implanted * optimized deep brain stimulation (dbs) settings (or at least 4 months of dbs programming) exclusion criteria: * other neurological diagnoses (co-existent alzheimer's or als) * no deep brain stimulation (dbs) * less than 4 deep brain stimulation (dbs) programming

Keywords: parkinsons disease essential tremor dbs depp brain stimulation
internet assisted obesity treatment enhanced with financial incentives

Conditions: Obesity

Summary: the investigators propose a randomized controlled trial to evaluate whether the addition of financial incentives to a high-quality, online behavioral weight loss intervention produces better weight losses than the online treatment alone.

overweight and obese but otherwise healthy participants (n=416) will be recruited in approximately equal numbers at two clinical centers, the university of south carolina and the university of vermont. eligible participants will be randomized to one of two conditions: 1) an 18-month, 36-session group internet behavioral weight control treatment (internet only) which replicates the intervention the investigators have implemented previously; or 2) the same 18-month, 36-session group internet treatment plus financial incentives for performance of 3 key self-management behaviors (internet+ incentive). both conditions will have access to the same web-based intervention platform and the same counselor-delivered intervention elements; the presence of economic incentives for behavioral and weight goals is the only difference between the conditions. assessments will be conducted at baseline, 2, 6, 12 and 18 months. cost data will be collected to inform cost effectiveness evaluations.

Eligibility criteria:
inclusion criteria: * over 18 * bmi between 25 and 50 * not currently pregnant or pregnant in the previous 6 months and currently breastfeeding or planning on becoming pregnant in 18 months * have a computer at home or at work with flashplayer, access to the internet, and a smart phone (to allow use of step counting aps) * free of medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component * not enrolled in another weight reduction program * not currently on medication that would affect weight loss exclusion criteria: * had a heart attack or stroke in the previous six months * had weight loss surgery * lost 10 pounds or more in the previous 6 months * currently taking medications for weight loss * required by their doctor to follow a special diet (other than low fat) * planning to move out of the area within 18 months * schedule conflicts making it difficult to attend online "chats" * live more than 60 minutes driving distance from either university of south carolina or university of vermont campuses

Keywords: weight loss financial incentives internet weight loss
anatomical shoulder™ inverse/reverse study

Conditions: Cuff-tear Arthropathy

Summary: the purpose of this study is to obtain outcomes data on the anatomical shoulder™ inverse/reverse system by analysis of standard scoring systems and radiographs. outcome data will be collected using the following standard scoring systems of which summary statistics will be provided: • constant and murley score to evaluate clinical parameters such as range of motion, power, level of pain and functional ability.

this is a multi-centre, non-comparative, prospective post-market surveillance study involving orthopaedic surgeons skilled in shoulder replacement surgery. each case enrolled will receive an anatomical shoulder™ inverse/reverse implant. all system components are ce-marked and commercially available. patients will be selected according to the subject selection criteria. all patients will undergo pre-operative, intra-operative and post-operative physical examination, radiographic evaluation according to the hospital's routine procedure and collection of quality of life metrics. follow-up evaluations are to be conducted at either 6 weeks or 6 months (according to the hospital's standard care plan) and thereafter at 1, 2, 5 and 10 years post hospital discharge. there are 5 study centres taking part in this project enrolling in total a maximum of 160 patients.

Eligibility criteria:
inclusion criteria: * age - 18 years minimum. * sex - male and female. * general health - the patient should be able to undergo surgery and participate in a follow-up program based upon physical examination and medical history. * informed consent - patient or patient's legal representative has signed a patient informed consent form. * indications - diagnosis of disease or trauma in the affected joint, including cuff-tear arthropathy, failure of prior rotator cuff surgery and irreparable rotator cuff tears associated with loss of glenohumeral stability with the indication for total shoulder arthroplasty. * the deltoid muscle has to be intact in all 3 parts (clavicular, acromial as well as spinal). exclusion criteria: * patient is skeletally immature. * patient is pregnant. * patient is unwilling or unable to cooperate in a follow-up program. * patient shows one of the following medical conditions - chronic fracture, acute fracture, axillary nerve lesion, severe loss of humeral or glenoid bone, paralysis of the deltoid muscle, active infection * patient requires one of the following medical interventions - implant revision, glenoid bone grafting, autografts

Keywords: inverse reverse shoulder
galectin-3 in septic and non-septic acute kidney injury

Conditions: Acute Kidney Injury; Sepsis

Summary: acute kidney injury (aki) is a common critical condition with high morbidity and mortality. the level of circulating galectin-3 (gal3) largely depends on renal function, so it is elevated in patients with aki or ckd; elevated gal3 also aggravates the progression of ckd after the onset of aki. the proinflammatory and profibrotic properties of gal3 may render it to be one of the key molecules mediating aki, ckd, and cardiorenal syndrome. in this prospective observational study, the investigators will explore the differences of gal3 levels among septic aki, non-septic aki, and non-aki patients and its correlation with prognosis, inflammation, and disease severity in the icu.

acute kidney injury (aki) is a common critical condition with high morbidity and mortality. not only can aki cause death in the acute phase, but also can it be associated with the development of chronic kidney disease (ckd) or the progression of ckd. galectins are members of a lectin family widely expressed in vertebrates, among which galectin-3 (gal3) is the most studied one. the level of circulating gal3 largely depends on renal function, so it is elevated in patients with aki or ckd; elevated gal3 also aggravates the progression of ckd after the onset of aki. the proinflammatory and profibrotic properties of gal3 may render it to be one of the key molecules mediating aki, ckd, and cardiorenal syndrome. however, the mechanisms of aki differ from different etiologies, and the process and extent of levels of gal3 may be also different, so its predictive value in prognosis may vary in different types of aki. in critically ill patients, aki is a common complication of sepsis, and sepsis is the most common trigger of aki. in this prospective observational study, the investigators will explore the differences of gal3 levels among septic aki, non-septic aki, and non-aki patients and its correlation with prognosis, inflammation, and disease severity in the icu.

Eligibility criteria:
inclusion criteria: * 1. 18 years old or more. * 2. the patient himself or his agent is able to provide informed consent and provide adequate information for the endpoint assessment. * 3. renal function was stable before this onset, and there was no evidence of plasma creatinine rising by 0.3 mg/dl within 3 months of study entry and not receiving rrt. exclusion criteria: * 1. age less 18 years old. * 2. there were previous acute kidney injury, kidney transplantation, chronic kidney disease, or with a glomerular filtration rate of less than 30 ml/min, or hepatorenal syndrome, or pregnancy. * 3. patients with an expected survival time of less than 6 months.
effect of pur003 on asthma

Conditions: Asthma; Lung Diseases; Bronchial Diseases

Summary: pur003 is an inhaled substance that is proposed to assist in the treatment of asthma. study objectives are to : 1. to evaluate the safety of pur003 in subjects with asthma, and 2. to evaluate the efficacy of pur003 in assisting the treatment of asthma.


Eligibility criteria:
inclusion criteria: 1. signed written informed consent. 2. ability and willingness to return to the outpatient clinic for repeated clinic visits and complete all assessments. 3. adult male or female subject, 18-60 years of age. 4. stable, mild asthma not requiring any medical treatment other than short acting inhaled bronchodilators, as needed. 5. no smoking within six months prior to entry 6. must be medically stable. 7. female subjects must have a negative pregnancy test 8. subjects of child bearing potential should be sexually inactive (abstinent) for 14 days prior to the first dose of study medication or using an acceptable form of birth control methods. exclusion criteria: 1. history or presence of significant co-existing chronic diseases. 2. history of asthma exacerbations or upper or lower respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) within four weeks of first visit. 3. pregnancy, breastfeeding. 4. abused alcohol or illicit drugs that required treatment. 5. participated in any other investigational drug evaluation within last 30 days. 6. scheduled to have elective or invasive medical intervention, procedure, or surgery within 6 months.

Keywords: asthma bronchial diseases lung diseases bronchitis respiratory tract diseases